Analyst picks & changes

Biogen Inc.


David Crossen of UBS Securities initiated coverage with a "buy" and a 12-18 month price target of $60. He anticipates earnings of 31 cents this year and a loss of $1 in

Read the full 351 word article

How to gain access

Continue reading with a
two-week free trial.